Back to Search
Start Over
Candidacy of adult patients with short bowel syndrome for treatment with glucagon-like peptide-2 analogues: A systematic analysis of a single centre cohort.
- Source :
- Clinical Nutrition; Jun2021, Vol. 40 Issue 6, p4065-4074, 10p
- Publication Year :
- 2021
-
Abstract
- The glucagon-like peptide-2 (GLP-2) analogue, teduglutide, allows to reduce the intravenous supplementation (IVS) dependency of patients with short bowel syndrome and intestinal failure (SBS-IF). The rate of candidacy of SBS-IF patients for the treatment is unknown. The candidacy for teduglutide treatment of our patient cohort was investigated by a systematic analysis. The indications, contraindications, special warnings and precautions for use of teduglutide, listed in the drug monographs and in the phase-III trial protocol were adopted to categorize the patients as non-candidates (NC), potential candidates (PC) or straight candidates (SC) for the treatment. All the SBS-IF adult patients who were cured at our centre were assessed according to their clinical status on January 1st, 2020. Seventy-nine patients were evaluated: 34.2% were NC due to risk of digestive malignancy, recent history of any other cancer, or listing for intestinal transplantation; 30.4% were PC, because of other premalignant conditions, risk of intestinal obstruction, entero-cutaneous fistulas, or severe co-morbidities; 35.4% were SC. The SC group showed the lowest requirement of IVS: the lowest number of days of infusion per week (p = 0.0054), the lowest amount of energy (p = 0.0110) and volume (p = 0.0136). This systematic analysis allowed a pragmatic categorization of the candidacy of patients with SBS-IF for GLP-2 analogue treatment. The SC group appeared to have the highest probability of a successful response to the treatment. A systematic analysis of SBS-IF patient candidate for GLP-2 analogue therapy would allow a homogeneous patient selection and facilitate the worldwide comparison of the results of clinical practice and research. • Short bowel syndrome with intestinal failure (SBS-IF) needs intravenous nutrition. • Intestinal rehabilitation therapy may allow weaning from intravenous nutrition. • The GLP-2 analogue, teduglutide, facilitates intestinal rehabilitation in SBS-IF. • The rate of candidacy for treatment with GLP-2 analogues is unknown. • A systematic analysis of SBS-IF patients for GLP-2 candidacy was developed, to homogenize the worldwide selection of SBS-IF patients for GLP-2 analogue treatment. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 02615614
- Volume :
- 40
- Issue :
- 6
- Database :
- Supplemental Index
- Journal :
- Clinical Nutrition
- Publication Type :
- Academic Journal
- Accession number :
- 151058623
- Full Text :
- https://doi.org/10.1016/j.clnu.2021.02.011